Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta‐analysis
Open accessAbstract
Objective: To systematically review and analyze the efficacy and tolerability of different antidepressant pharmacologic treatments for depressive symptoms in Parkinson's disease (PD) Methods: We searched PubMed, EMBASE, Cochrane database (CENTRAL), clinicaltrials.gov, and bibliographies for randomized controlled trials investigating the efficacy of antidepressant medications versus a non‐treatment, placebo, or active treatment groups for depressive symptoms in PD. Twenty of 3191 retrieved studies (1893 patients) were included, but not all could be meta‐analyzed. We used a random‐effects model meta‐analysis to compare depression scores between an active drug and placebo or control group then used a network meta‐analysis to compare the effectiveness of different antidepressant classes. The primary outcome was the efficacy of different classes of antidepressant medications in PD patients with depressive symptoms, measured by standardized mean difference (SMD) in depression score from baseline compared with control. Results: Pairwise meta‐analysis suggested that type B‐selective monoamine oxidase inhibitors (SMD = −1.28, CI = −1.68, −0.88), selective serotonin reuptake inhibitors (SMD = −0.49, CI = −0.93, −0.05), and tricyclics (SMD = −0.83, CI = −1.53, −0.13) are effective antidepressants in PD. Network meta‐analysis showed that monoamine oxidase inhibitors had the largest effect on depression in PD (SMD (vs selective serotonin reuptake inhibitors) = −0.78, CI = −1.55, −0.01), but these might not be considered traditional antidepressants given their type B selectivity. Conclusions: Although limited by few data, this review suggests that multiple antidepressant classes are potentially efficacious in the treatment of depression in PD, but that further comparative efficacy and tolerability research is needed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antidepressants improve motor symptoms in Parkinson's disease.
“and motor symptoms in Parkinson's disease289.”
From Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management (2023) · cites this paper as [289]
Results §3.3.2 reports a significant reduction in motor symptoms with SSRIs versus placebo, but no significant difference for SNRIs; the MAOI trials did not report motor scores. The claim overgeneralizes the finding from one antidepressant class to antidepressants as a whole. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225 · see citing works
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · see citing works
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689 · see citing works
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445 · see citing works
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239 · see citing works
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · see citing works
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A. E., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., STARKSTEIN, S. E., Weintraub, D. A., Poewe, W. H., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 681 · see citing works
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · see citing works
Thobois, S., Ardouin, C., Lhommée, E., Klinger, H., Lagrange, C., Xie, J., Fraix, V., Braga, M.-C. C., Hassani, R., Kistner, A., et al. (2010) · Brain · doi:10.1093/brain/awq032 · Cited by 519 · see citing works
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M. A., Dobkin, R. D., Marín, H., Mark, M. H., Gara, M. A., Buyske, S. G., Bienfait, K., & Dicke, A. (2008) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 413 · see citing works
STARKSTEIN, S. E., Mayberg, H. S., Leiguarda, R. C., Preziosi, T. J., & Robinson, R. G. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.5.377 · Cited by 371 · see citing works
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
Richard, I., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J. L., Ramos, C. S., Brodsky, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182516244 · Cited by 336 · see citing works
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 307 · see citing works
Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations
Borgohain, R., Szász, J. A., Stanzione, P., Meshram, C., Bhatt, M. H., Chirilineau, D., Stocchi, F., Lucini, V., Giuliani, R., Forrest, E. A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25751 · Cited by 293 · see citing works
Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008) · Movement Disorders · doi:10.1002/mds.21966 · Cited by 273 · see citing works
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · see citing works
Müller, B., Aßmus, J., Herlofson, K., Larsen, J. P., & Tysnes, O. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.07.010 · Cited by 248 · see citing works
Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease
Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, F., Bracco, F., Zappia, M., Musch, B., & and the Depression/Parkinson Italian Study Group (2006) · Journal of Neurology · doi:10.1007/s00415-006-0067-5 · Cited by 247 · see citing works
Weintraub, D. A., Newberg, A. B., Cary, M. S., Siderowf, A. D., Moberg, P. J., Kleiner‐Fisman, G., Duda, J. E., Stern, M. B., Mozley, D. P., & Katz, I. R. (2005) · PubMed · Cited by 245 · see citing works
Mortality in Parkinson's disease and its association with dementia and depression
Hughes, T. A., Ross, H., Mindham, R. H. S., & SPOKES, E. G. S. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00292.x · Cited by 220 · see citing works
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214 · see citing works
Andersen, J., Aabro, E., Gulmann, N. C., Hjelmsted, A., & Pedersen, H. E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1980.tb03028.x · Cited by 211 · see citing works
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164 · see citing works
Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis
Bomasang-Layno, E., Fadlon, I., Murray, A. N., & Himelhoch, S. S. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.018 · Cited by 139 · see citing works
Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial
Wermuth, L., Sørensen, P. S., Timm, S., Christensen, B., Utzon, N. P., Boas, J., Dupont, E., Hansen, E., Magnussen, I., Mikkelsen, B. O., et al. (1998) · Nordic Journal of Psychiatry · doi:10.1080/08039489850139049 · Cited by 126 · see citing works
Hu, X., Song, X., Yuan, Y., Erfeng, L., Liu, J., Liu, W., & Liu, Y. (2014) · Movement Disorders · doi:10.1002/mds.26087 · Cited by 125 · see citing works
Carod-Artal, F. J., Ziomkowski, S., Mesquita, H., & Martínez‐Martín, P. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.011 · Cited by 121 · see citing works
Antonini, A., Tesei, S., Zecchinelli, A., Barone, P., Gaspari, D. D., Canesi, M., Sacilotto, G., Meucci, N., Mariani, C. B., & Pezzoli, G. (2006) · Movement Disorders · doi:10.1002/mds.20895 · Cited by 118 · see citing works
SSRIs in the treatment of depression in Parkinson's disease
Leentjens, A. F. G., Vreeling, F. W., Luijckx, G. J., & Verhey, F. R. J. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.865 · Cited by 117 · see citing works
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
Smith, K. M., Eyal, E., & Weintraub, D. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2472 · Cited by 106 · see citing works
Barone, P., Santangelo, G., Morgante, F., ONOFRJ, M. C., Meco, G., Abbruzzese, G., Bonuccelli, U., Cossu, G., Pezzoli, G., Stanzione, P., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12724 · Cited by 104 · see citing works
Skapinakis, P., Bakola, E., Salanti, G., Lewis, G., Kyritsis, A. P., & Mavreas, V. G. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-49 · Cited by 104 · see citing works
Anxiety, depression, and quality of life in Parkinson's disease
Quelhas, R., & Costa, M. (2009) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.2009.21.4.413 · Cited by 100 · see citing works
Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial
Ávila, A., Cardona, X., Martín‐Baranera, M., Maho, P., González‐Sastre, F., & Bello, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088908.24613.db · Cited by 88 · see citing works
Liu, J., Dong, J., Wang, L., Su, Y., Yan, P., & Sun, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076651 · Cited by 83 · see citing works
The longitudinal impact of depression on disability in Parkinson disease
Pontone, G. M., Bakker, C. C., Chen, S., Mari, Z. K., Marsh, L., Rabins, P. V., Williams, J. R., & Bassett, S. S. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4350 · Cited by 72 · see citing works
Self-citationThe use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease
Werneck, A. L. D. S., de Rosso, A. L. Z., & Vincent, M. B. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000300007 · Cited by 46 · see citing works
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
Lim, T. T., Kluger, B. M., Rodriguez, R. L., Malaty, I. A., Palacio, R., Ojo, O. O., Patel, S., Gujrati, Y., Nutter, B., Swartz, C., et al. (2015) · Movement Disorders · doi:10.1002/mds.26429 · Cited by 45 · see citing works
Amitriptyline in the treatment of headache in patients with Parkinson's disease
Indaco, A., & Carrieri, P. B. (1988) · Neurology · doi:10.1212/wnl.38.11.1720 · Cited by 44 · see citing works
P01-29 - Depression in Parkinson's Disease- Searching for the most Potent Antidepressant
Djokic, G., Zivkovic, N., Pavicevic, D., & Lazic, D. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)70248-0 · Cited by 5 · see citing works
Vasile, D., Vasiliu, O., Vasile, M. L., Bogdan, V., Badescu, E., Mangalagiu, A. G., Stanescu, B. A., & Petrescu, B. M. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)70986-x · Cited by 5 · see citing works
P.2.c.016 Sertraline versus mirtazapine in treatment of depression in Parkinson's disease
Djokic, G., Pavicevic, D., Zivkovic, N., Nenadović, M., Nenadović, N., & Duišin, D. (2010) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(10)70531-9 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [19]Sutton AJ Abrams KR Jones DR Sheldon TA Song F Assessing Between Study Heterogeneity. Methods for Meta-analysis in Medical Research West Sussex, UK John Wiley & Sons, Ltd 2000
- [32]Trivedi A Comparative study of efficacy for bupropion vs. sertraline (SSRI) in depression with Parkinsons disease [conference presentation] International Psychogeriatrics [abstracts from The International Psychogeriatric Association Eleventh International Congress Chicago, United States 17–22 August 2003] 2003 15 Suppl 2
- [39]Malaty I Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease 2012 26769459
Cited by
Sorted by citations
The neuropsychiatry of Parkinson’s disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, K., Dobkin, R., Leentjens, A., Rodríguez-Violante, M., & Schrag, A. (2022) · Lancet Neurology · doi:10.1016/s1474-4422(21)00330-6 · Cited by 350 · see citing works
Berk, M., Köhler‐Forsberg, O., Turner, M., Penninx, B. W. J. H., Wrobel, A., Firth, J., Loughman, A., Reavley, N. J., McGrath, J. J., Momen, N. C., et al. (2023) · World Psychiatry · doi:10.1002/wps.21110 · Cited by 336 · see citing works
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 314 · see citing works
The neuropsychiatry of Parkinson's disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, К. R., Dobkin, R., Leentjens, A., Rodriguez-Violante, M., & Schrag, A. E. (2022) · UCL Discovery (University College London) · Cited by 181 · see citing works
Psychiatric Manifestation in Patients with Parkinson's Disease
Han, J. W., Ahn, Y. D., Kim, W.-S., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J.-M. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e300 · Cited by 127 · see citing works
Management of psychiatric and cognitive complications in Parkinson’s disease
Weintraub, D. A., Aarsland, D., Biundo, R., Dobkin, R. D., Goldman, J. G., & Lewis, S. J. G. (2022) · BMJ · doi:10.1136/bmj-2021-068718 · Cited by 91 · see citing works
Drug Choices and Advancements for Managing Depression in Parkinson's Disease
Assogna, F., Pellicano, C., Savini, C., Macchiusi, L., Pellicano, G. R., Alborghetti, M., Caltagirone, C., Spalletta, G., & Pontieri, F. E. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191016094857 · Cited by 81 · see citing works
Optimal Treatment of Depression and Anxiety in Parkinson's Disease
Pontone, G. M., & Mills, K. A. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.02.037 · Cited by 67 · see citing works
Self-citationParkinson and depression: review and outlook
Laux, G. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02456-3 · Cited by 52 · see citing works
Angelopoulou, E., Stanitsa, E., Karpodini, C. C., Bougea, A. M., Kontaxopoulou, D., Fragkiadaki, S., Koros, C., GEORGAKOPOULOU, V. E., Fotakopoulos, G., Koutedakis, Y., et al. (2023) · Medicina · doi:10.3390/medicina59081454 · Cited by 46 · see citing works
Pagonabarraga, J., Álamo, C., Castellanos, M., Díaz, S., & Manzano, S. (2023) · Brain Sciences · doi:10.3390/brainsci13020318 · Cited by 43 · see citing works
Agüera-Ortíz, L., García-Ramos, R., Pérez, F. J. G., López‐Álvarez, J., Rodríguez, J. M. M., Rodríguez, F. J. O., Pueyo, J. O., Valero, C. P., & Porta-Etessam, J. (2021) · Parkinson s Disease · doi:10.1155/2021/6621991 · Cited by 41 · see citing works
Feng, S., Wang, X., Wang, Y., Yuan, Y., Li, Z., Chen, N., Wang, Z., & Zhang, Y. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500282 · Cited by 36 · see citing works
Wang, X., Feng, S., Wang, Y., Chen, B., Wang, Z., Chen, N., & Zhang, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175070 · Cited by 32 · see citing works
Kawakami, I., Iga, J., Takahashi, S., Lin, Y., & Fujishiro, H. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13485 · Cited by 27 · see citing works
Non-Motor Symptoms: The Hidden Face of Parkinson’s Disease
Cattaneo, C., Fabbrini, A., Belvisi, D., Aiello, F., Marchet, F., & Fabbrini, G. (2025) · Cells · doi:10.3390/cells15010042 · Cited by 23 · see citing works
Suicide in Parkinson’s Disease: A Systematic Review
Berardelli, I., Belvisi, D., Nardella, A., Falcone, G., Lamis, D. A., Fabbrini, G., Berardelli, A., Girardi, P., & Pompili, M. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190703093345 · Cited by 22 · see citing works
Desvenlafaxine in the treatment of major depression: an updated overview
Norman, T. R., & Olver, J. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1900826 · Cited by 20 · see citing works
Elefante, C., Brancati, G. E., Bacciardi, S., Mazzucchi, S., Prete, E. D., Palermo, G., Frosini, D., Bonuccelli, U., Ceravolo, R., Lattanzi, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112302 · Cited by 18 · see citing works
Weintraub, D. A., & Irwin, D. J. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001151 · Cited by 18 · see citing works
Ruan, X., Lin, F., Wu, D., Chen, L., Weng, H., Yu, J., Wang, Y.-Q., Chen, Y., Chen, X., Ye, Q., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.728083 · Cited by 14 · see citing works
Vismara, M. E. M., Benatti, B., Nicolini, G., Cova, I., Monfrini, E., Fonzo, A. D., Fetoni, V., Viganò, C. A., Priori, A., & Dell’Osso, B. M. (2022) · BMC Neurology · doi:10.1186/s12883-022-02668-4 · Cited by 14 · see citing works
The pharmacological management of the behavioral aspects of Parkinson’s disease: an update
Campagnolo, M., Emmi, A., Biundo, R., Fiorenzato, E., Batzu, L., Chaudhuri, К. R., & Antonini, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2240228 · Cited by 13 · see citing works
Stocchi, F., Antonini, A., Barone, P., Bellelli, G., Fagiolini, A. M., Ferini‐Strambi, L., Sorbi, S., & Padovani, A. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06740-w · Cited by 12 · see citing works
Ovlyakulov, B., Hu, B., Kan, H.-Y., Guo, Q., Li, X., Fan, H.-H., Wu, H., Wang, J., Zhang, X., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112715 · Cited by 11 · see citing works
Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease
Ziaei, E., Ardestani, P. E., & Chitsaz, A. (2022) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_790_21 · Cited by 12 · see citing works
Gao, R., Zhao, P., & Yan, K. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01378-8 · Cited by 10 · see citing works
Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale
Amstutz, D., Sousa, M., Maradan‐Gachet, M. E., Debove, I., Lhommée, E., & Krack, P. (2024) · Revue Neurologique · doi:10.1016/j.neurol.2024.11.004 · Cited by 11 · see citing works
Approaches for treating neuropsychiatric symptoms in Parkinson’s disease: a narrative review
Rodríguez-Antigüedad, J., Olmedo‐Saura, G., Pagonabarraga, J., Martínez‐Horta, S., & Kulisevsky, J. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251336903 · Cited by 8 · see citing works
Management of Anxiety in Parkinson's Disease
Berry, A. J., Costello, H., Jesús, S., Price, G. W., & Jha, A. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70144 · Cited by 8 · see citing works
Pathogenesis, clinical features, and treatments of depression in Parkinson's disease
Milyukhina, I. V. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-2-93-99 · Cited by 7 · see citing works
Vortioxetine Improved Depressive State In Parkinson’s Disease
Yoshimura, R., Ikenouchi, A., Okamoto, N., & Konishi, Y. (2021) · Cureus · doi:10.7759/cureus.15750 · Cited by 7 · see citing works
Cognitive and executive impairments in Parkinson’s disease psychosis: a Bayesian meta-analysis
Pisani, S., Gosse, L., Wieretilo, R., Ffytche, D. H., Velayudhan, L., & Bhattacharyya, S. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-331028 · Cited by 7 · see citing works
Lewy Body Degenerations as Neuropsychiatric Disorders
Hinkle, J. T., & Pontone, G. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.003 · Cited by 7 · see citing works
Self-citationDepression After Parkinson’s Disease: Treated Differently or Not At All?
DeMarco, E. C., Zhang, Z., Al-Hakeem, H., & Hinyard, L. (2022) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221090217 · Cited by 6 · see citing works
Cognitive dysfunction and neuropsychiatric aspects of Parkinson's disease
Austgen, G., & Marsh, L. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.009 · Cited by 6 · see citing works
Ballmann, C. G., Schmid, D. G., Rogers, R. R., Oakes, H. K., & Osburn, S. C. (2026) · Neurology International · doi:10.3390/neurolint18030045 · Cited by 4 · see citing works
Miliukhina, I. V. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-5-40-45 · Cited by 4 · see citing works
Amine Precursors in Depressive Disorders and the Blood-Brain Barrier
Sharma, H. S., & Sharma, A. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_423-1 · Cited by 4 · see citing works
Orayj, K. M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325521 · Cited by 4 · see citing works
Girges, C., de Roquemaurel, A., Vijiaratnam, N., Foley, J. A., Candelario, J., Salazar, M., Milabo, C., Esperida, J. O., Grover, T., Akram, H., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251354933 · Cited by 3 · see citing works
Neuroimaging Advances in Neuropsychiatric Symptoms Associated with Parkinson’s Disease
Zhang, Q., Kim, J. I., & Lu, Q. (2025) · Brain Conflux · doi:10.71321/z4638252 · Cited by 3 · see citing works
Atewogboye, O., Taylor, J., & Harrison, J. R. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2562151 · Cited by 2 · see citing works
Recent hospitalization and risk of antidepressant initiation in people with Parkinson’s disease
Hämäläinen, I., Tiihonen, M., Hartikainen, S. A., & Tolppanen, A. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03698-w · Cited by 2 · see citing works
Regulation | Monoamine Oxidases
Raghavan, S., Baskin, D. S., & Sharpe, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00343-1 · Cited by 2 · see citing works
Perspective: Depression in Persons with Parkinson's Disease
Leentjens, A. F. G., & Pontone, G. M. (2026) · Movement Disorders · doi:10.1002/mds.70285 · Cited by 1 · see citing works
Self-citationMood Disorders in Parkinson’s Disease
Tsai, P., & Gopalakrishna, G. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009039291.010 · Cited by 1 · see citing works
Miliukhina, I. V. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-78-82 · Cited by 1 · see citing works
Depressive symptoms in selected neurological disorders
Končelíková, D. (2020) · Neurologie pro praxi · doi:10.36290/neu.2020.047
Antidepressivatherapie bei neurologischen Erkrankungen
Höppner‐Buchmann, J. (2021) · DGNeurologie · doi:10.1007/s42451-021-00375-x
Neuropsychiatrische symptomen bij de ziekte van Parkinson: een gevalsbeschrijving
Ketelaere, L. D., Eede, F. V. D., Waele, S. D., Volder, I. D., & Crosiers, D. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.031
Amine Precursors in Depressive Disorders and the Blood-Brain Barrier
Sharma, H. S., & Sharma, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_423
Gao, R., Zhao, P., & Yan, K. (2023) · Research Square · doi:10.21203/rs.3.rs-2450447/v1
Uso de fármacos antidepresivos en neurología
García-Alberca, J. M. (2023) · Kranion · doi:10.24875/kranion.m23000058
Studying Neuropsychiatric Symptoms, Depression, Anxiety in Parkinson’s Disease
Kayser, S., & Groppa, S. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_6
Neuropsychiatric Manifestations in Parkinson Disease
Weintraub, D. A., Gallagher, J., & Stern, M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.015
(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21322-9.00027-8
Páez‐García, S., Ramírez-Triana, J., Folleco-Insuasty, L., Orozco‐Castro, S., de Castro, S. F., Garcia-Cifuentes, E. R., & Cerquera‐Cleves, C. (2025) · Acta neurológica colombiana · doi:10.22379/anc.v41i4.1974
Hämäläinen, I., Tiihonen, M., Hartikainen, S., & Tolppanen, A.-M. (2024) · Figshare · doi:10.6084/m9.figshare.26555480
Pytel, B., Márton, Z., Kocsa, J., Berta, G., Kovács, L. Á., Farkas, J., Füredi, N., Havasi, Z., Gaszner, B., & Gaszner, B. (2026) · GeroScience · doi:10.1007/s11357-026-02475-6
Karageorgiou, V., Skapinakis, P., Michopoulos, I., Mitrou, P., Thireos, E., & Gournellis, R. J. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70809
Repurposing existing drugs for Parkinson's disease management
Abouelmagd, M. E., Messak, M., Gadelmawla, A. F., & Kundu, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-54032-5.00007-3
- Authors
- Mills, K. A., Greene, M. C., Dezube, R., Goodson, C., Karmarkar, T., & Pontone, G. M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Mills, Kelly A.
- ORCID
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2017-12-13
- Volume
- 33
- Issue
- 4
- Pages
- 642-651
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- PMC
- PMC5992618
- OpenAlex
- W2771424262
- Cited by
- 63
- References
- 43
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 5 · 2023: 8 · 2022: 14 · 2021: 12 · 2020: 4 · 2019: 5 · 2018: 1
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- International Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Advancing Translational Sciences (KL2TR001077)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Parkinson's disease, depression, antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase B inhibitors, antidepressant efficacy, antidepressant tolerability, depressive symptoms
- MeSH terms
- Antidepressive Agents, Antidepressive Agents, Tricyclic, Benzylamines, Depressive Disorder, Diagnostic Tests, Routine, Humans, Parkinson Disease, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
